613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

Phase 2 study of brexu cel in minimal residual disease positive B cell acute lymphoblastic leukemia

Real world outcomes of asciminib in relapsed refractory Philadelphia chromosome positive B ALL and blast Phase CML

Ibrutinib plus blinatumomab in Relapsed Refractory B cell acute lymphoblastic leukemia Results of A phase 2 study

Two decades of risk directed therapy for childhood acute lymphoblastic leukemia in a resource limited setting Lessons from a modified st jude total XV protocol

Deeper remission achievement and longer leukemia free survival with inati cel as consolidation therapy in allogeneic transplant ineligible adolescent and adult patients with B ALL

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed refractory r r B cell acute lymphoblastic leukemia B ALL primary analysis of a Phase 1 2 study

Consolidation with CAR T cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B cell acute lymphoblastic leukemia after receiving dose dense mini hyper CVD with inotuzumab ozogamicin and blinatumomab

Auto HSCT combined with blinatumomab as an allo HSCT sparing strategy in newly diagnosed B ALL Phase II trial results

Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B cell acute lymphoblastic leukemia in morphologic remission

Efficacy and safety of melphalan TBI based conditioning regimens MCAC TCAC for autologous HSCT in adult acute lymphoblastic leukemia A multicenter prospective cohort study

Treatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia using hypercvad with ponatinib is associated with excellent survival with selective use of blinatumomab and allogeneic hematopoietic cell transplantation

SWOG 1318 Combination of dasatinib prednisone and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia   longer follow up and predictors of outcomes

First promising results in younger adult patients

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B cell ALL treated with inotuzumab ozogamicin and low dose chemotherapy in first line therapy A graall study

Comparison of simulated exposure of inotuzumab ozogamicin with and without dose capping in overweight and obese patients with relapsed refractory acute lymphoblastic leukemia